A new Global Plasma Fibrinolytic Assay for the rapid analysis of hyper-/hypo-Fibrinolysis: relationship with blood lipids and inflammatory markers

Abstract number: P1837

Zouaoui Boudjeltia^* K., Amiral† J., Vissac† A.-M., Deschepper‡ N., Saccomando‡ E., Vanhaeverbeek^* M., Cauchie‡ P.

‡CHU de Charleroi – Hôpital A Vésale, Belgium ^*CHU de Charleroi, Belgium; †Hyphen Biomed, France;

Several studies already emphasized the importance of fibrinolytic disturbances in the physiopathology of the vascular wall. The body's fibrinolytic potential is difficult to evaluate in clinical practice. We developed a semiautomatic device for a rapid evaluation of the Fibrinolytic activity, with a continuous clot lysis measurement method, allowing a standardization of the test [1]. The lysis time was expressed as the time required for reaching the peak of the clot fibrinolytic process kinetics, and was computed from a mathematical analysis of the recorded lysis curve. Using this device, we developed a new Global Plasma Fibrinolytic Assay (GPFA) This assay allows evaluating as well as hyper-fibrinolysis as hypo-fibrinolysis, this latter being associated with an increased risk of cardio-vascular and thrombo-embolic diseases. We correlated the GPFA with blood lipids (Total Cholesterol (TC), HDL-c, LDL-c, Triglycerides (TG), TC/HDL-c) and inflammatory markers (hs-CRP, fibrinogen, monocyte counts) on 25 samples from unselected patients (16 women and nine men). The correlation were depicted using a Spearman's test. Results – median (25%-75%), GPFA: 214 (156–254) min, fibrinogen: 394 (327–445) mg%, hs-CRP: 0.4 (0.12–0.67) mg dL, TC: 226 (181–250) mg%, TG: 107 (62–160) mg%, HDL-c: 49.5 (43–64.5) mg%, LDL-c: 145 (106–167) mg%, monocyte counts: 480 (415–512) × 1000 cells µL^-1. GPFA was significantly correlated with TG (R = 0.64; P = 0.006), HDL (R = -0.64; P = 0.007), TC/HDL (R = 0.68; P = 0.003), fibrinogen (R = 0.50; P = 0.01) and monocyte counts (R = 0.68; P = 0.003). With these limited data we observed that GPFA is well related with biological parameters recognized as being cardiovascular risk factors. The routine use of this new fibrinolytic test could be useful for diagnosing various situations such as systemic hypo- or hyper-fibrinolysis and it could be included to the assay panel estimating the biological factors with predictive or diagnostic value for atherothrombosis.

1   BMC Biotechnology2002; 2: 8.